COLDSKY.CN – GVC Capital（GGV纪源资本), leading Beijing Kunlun Tech Co (北京昆仑万维昆仑互联网智能基金), Shanghai Guofang FOF（国方母基金）and Alwin Capital（雅惠资本） injected 150 million yuan in Series B+ round of financing of Keya Medical(科亚医疗), an AI-driven medical imaging start-up.
In the diagnosis and treatment of coronary artery disease (CAD), the most common type of heart disease, Fractional flow reserve (FFR), which measures the blood flow reduction caused by vessel narrowing, is accepted as the reference standard for assessing the functional significance of the stenotic lesions.
The company behind DeepVessel FFR, an innovative CT-FFR technology, won the registration certificate approving the technology for clinical use by the National Medical Products Administration (NMPA) in January, the first AI product approved for marketing by NMPA.
The technology is built on the latest advances from the computer vision industry as optimized by scientific team for medical image analysis, according to the company.
The non-invasive technique can achieve 89% diagnostic accuracy and the FFR values can be observed at any location in the coronary tree.
Supported by medical experts including Professor Yuji Zhou, Vice President of Beijing Anzhen Hospital affiliated with Capital Medical University, the company has entered into cooperation with over 200 public hospitals and co-established nearly 100 AI diagnosis centres.
